On Monday, June 15, 2020, the U.S. Food and Drug Administration removed the Emergency Authorization Use (EAU) of two malaria drugs to treat COVID-19, saying that they are “unlikely to be effective.”

Both hydroxychloroquine (brand name Plaquenil) and chloroquine were heavily promoted by President Trump after a handful of small, poorly controlled studies showed that they could work in treating the disease.

The FDA reported that further studies had shown that the two drugs were unlikely to be effective in stopping the virus, and that current national treatment guidelines do not recommend using them outside of clinical trials.

Hydroxychloroquine is a low-risk ototoxic drug. Please refer to this feature article for more information.

Share this

Related Posts

Cortical Changes in Total and Partial Vestibular Dysfunction, As Measured by EEG

Where do U.S. Adults Obtain Their Usual Healthcare?

Use of Dietary Supplements in the United States

Recent Posts

Cortical Changes in Total and Partial Vestibular Dysfunction, As Measured by EEG

Study Supports Expanded Candidacy for Pediatric Cochlear Implantation For children less than two years of age, current Food and Drug Administration (FDA) candidacy criteria for…

Read More

Academy Submits Comments on MPFS Proposed Rule CY 2027

On behalf of the membership, the American Academy of Audiology has submitted comments on the Centers for Medicare and Medicaid Services’ (CMS) Calendar Year (CY)…

Read More

Where do U.S. Adults Obtain Their Usual Healthcare?

While we know that primary care providers can be a source of referrals for audiologic care, have you wondered how many individuals have a regular…

Read More